logo
Plus   Neg
Share
Email

Medtronic: FDA Approves Revised Commercial Labeling For Intellis Platform

Medtronic plc (MDT) announced the FDA has approved revised commercial labeling for the Intellis Platform with Differential Target Multiplexed programming for the treatment of chronic, intractable back and leg pain. The company noted that the new labeling will include study outcomes from a multicenter randomized control trial reflecting superior back pain relief with Differential Target Multiplexed Spinal Cord Stimulation when compared to conventional Spinal Cord Stimulation.

Charlie Covert, vice president and general manager, Pain Therapies within the Neuromodulation business, which is part of the Neuroscience Portfolio at Medtronic, said: "The updated labeling further strengthens the credibility of the outcomes from this therapy, and parallels the profound benefits our clinician partners are seeing with their own patients."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Performance Food Group Co. announced Tuesday its agreement to acquire Core-Mark Holding Co., Inc., a wholesale distributor to the convenience retail industry, in around $2.5 billion stock and cash transaction, including net debt. In pre-markey activity on Nasdaq, Core-Mark shares were gaining around 9 percent to trade at $45.86. Retail giant Walmart Inc. reported Tuesday a profit for the first quarter of fiscal 2022 that declined 31.6 percent from last year, hurt by net losses on equity investments, However, adjusted earnings per share and quarterly revenues topped analysts' expectations. The retailer also raised its guidance for the second quarter and for the full-year 2022. European Medicines Agency or EMA announced that Comirnaty, the COVID-19 vaccine developed by Pfizer and BioNTech, can have more flexible storage conditions, including up to one month in a normal fridge. The proposed change in the approved storage conditions, recommended by EMA's human medicines committee or CHMP, will help in easy handling of the vaccine in vaccination centres across the EU.
Follow RTT